SCHEMBL17075232

SCHEMBL17075232

NC(=O)CN1CCC(CC(F)(F)F)c2ccccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.39
TEAD1 P28347 1/20 0.38
ALDH1A1 P00352 4/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
OPRK1 P41145 1/20 0.35
PRKACA P17612 1/20 0.34
PRKACG P22612 1/20 0.34
PRKACB P22694 1/20 0.34
RBP4 P02753 2/20 0.33
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17075236 0.82 CYP2C19 (0.40) CYP2C19TEAD1ALDH1A1MAPTKDM4E
SCHEMBL17075230 0.80 HTR2A (0.34) TEAD1ALDH1A1MEN1ALOX15KMT2A
SCHEMBL17075184 0.77 ALDH1A1 (0.39) CYP2C19TEAD1ALDH1A1MAPTKDM4E
SCHEMBL17075141 0.76 ALDH1A1 (0.39) CYP2C19ALDH1A1MAPTKDM4EMEN1
SCHEMBL17075119 0.76 ALDH1A1 (0.40) CYP2C19ALDH1A1MAPTKDM4EMEN1
SCHEMBL17075110 0.73 ALDH1A1 (0.36) CYP2C19TEAD1ALDH1A1MAPTKDM4E
SCHEMBL17075131 0.73 ALDH1A1 (0.38) CYP2C19ALDH1A1MAPTKDM4EMEN1
SCHEMBL17075125 0.71 ALDH1A1 (0.39) CYP2C19ALDH1A1MAPTKDM4EMEN1
SCHEMBL17075104 0.70 ALDH1A1 (0.38) CYP2C19ALDH1A1MAPTKDM4EMEN1
SCHEMBL17075092 0.69 TMEM97 (0.38) CYP2C19ALDH1A1MAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3116874-B1 HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL ABBVIE DEUTSCHLAND (DE) 2018-02-28 EP disclosed
US-20170112851-A1 HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL AbbVie Deutschland GmbH & Co. KG (DE) 2017-04-27 US disclosed
US-9540376-B2 Hexahydrodiazepinoquinolines carrying a substituted alkyl radical AbbVie Deutschland GmbH & Co. KG (DE) 2017-01-10 US disclosed
US-20150259346-A1 HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL AbbVie Deutschland GmbH & Co. KG (DE) 2015-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170112851-A1 HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL HTR2C, HTR2A, HTR3C CYP2C19 110/4885TEAD1 3351/4885ALDH1A1 866/4885
US-20150259346-A1 HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL HTR2C, HTR2A, HTR3C CYP2C19 110/4885TEAD1 3351/4885ALDH1A1 866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.